European Parliament

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
13 June 2012
E-005922/2012
Question for written answer
to the Commission
Rule 117
Cornelis de Jong (GUE/NGL) , Bas Eickhout (Verts/ALE) , Judith A. Merkies (S&D) and Keith Taylor (Verts/ALE)

 Subject: Possible postponement of complete trade ban on cosmetics tested on animals
 Answer(s) 

The EU Cosmetics Directive aims to phase out animal testing. It established a prohibition on the testing of finished cosmetic products (since 2004) and cosmetic ingredients (since 2009) on animals and a prohibition on the marketing in the EU of finished cosmetic products and ingredients included in cosmetic products which were tested on animals outside the EU. The latter marketing ban applies since 2009 for all human health effects with the exceptions of repeated-dose toxicity, reproductive toxicity and toxicokinetics. For these health effects, the ban will apply step by step but with a maximum cut-off date of 10 years after the entry into force of the directive (11 March 2013), irrespective of the availability of alternative non-animal tests.(1)

1. Does the Commission agree that a case-by-case derogation would mean a delay in the complete marketing ban on animal testing, and that with this third delay the Commission will lose credibility with the citizens of Europe?

2. Given that 80-90 % of the ingredients have a broader scope of application than cosmetics only(2) and that these substances can be tested under other legislation, for instance the legislation on chemicals and pharmaceuticals, will these ingredients also be banned for use in cosmetic products as of 11 March 2013?

3. Since toxicokinetics is one of the health effects for which no alternatives will be ready by 2013, according to the scientific review cited, while microdosing is a technique which enables research to be carried out on toxicokinetics in humans and is already in use in the pharmaceutical industry and in contract research companies, can the Commission state if, and if so how, microdosing is being investigated further as a possible promising technique for studying toxicokinetic features of substances which are under investigation for use in cosmetic products?

(1)http://ec.europa.eu/consumers/sectors/cosmetics/animal-testing/index_en.htm (accessed on 15 April 2012).
(2)Report on the Development, Validation and Legal Acceptance of Alternative Methods to Animal Tests in the Field of Cosmetics (2008) — report from the Commission to the European Parliament and the Council, Brussels, 16.9.2010, COM(2010)0480.

 OJ C 182 E, 27/06/2013
Last updated: 28 June 2012Legal notice